Celsion to Present at the 9th Annual Needham Life Sciences Conference

Wednesday, June 9, 2010 Education News J E 4

COLUMBIA, Md., June 8 Celsion Corporation (Nasdaq: CLSN) announced today that Michael H. Tardugno, Celsion's President and CEO, will present at the 9th Annual Needham Life Sciences Conference on Thursday, June 10th at 11:20 A.M. ET at the New York Palace Hotel in New York City. An audio webcast of the corporate presentation will be available on Celsion's website at

The Needham Life Sciences Conference is a leading industry event attracting over 100 healthcare companies. The conference provides participating companies with the opportunity to present to institutional investors and industry experts.

About Celsion

Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has licensed ThermoDox(R) to Yakult-Honsha for the Japanese market and has a partnership agreement with Phillips Medical to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.

For more information on Celsion, visit our website:

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

Contact: Marcy Nanus The Trout Group, LLC 646-378-2927 or

SOURCE Celsion Corporation


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Watson to Present at the Goldman Sachs 31st Annual...
Phase 2b Clinical Trial Results Show Aerovance's A...